Get Alnylam Pharmaceuticals Inc (ALNY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Find the latest Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
Get the latest insights on Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) with press releases and corporate news to help you in your trading and investing decisions.
ALNY Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced +58.85% Alnylam Pharmaceuticals, Inc. price and volume Combination chart with 2 data series. Chart represents Alnylam Pharmaceuticals, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The...
Regeneron Pharmaceuticals Inc4,444,4453.41--3/31/25 T. Rowe Price Investment Management, Inc.4,418,1453.3933,6963/31/25 Baillie Gifford & Co.3,657,6072.81-382,6523/31/25 T. Rowe Price Associates, Inc.3,406,3662.61178,2643/31/25
Use Futu NiuNiu to view Alnylam Pharmaceuticals (ALNY)'s stock price, real-time quotes, latest news, historical trend charts, financial information and quotes.
The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
4,736,842 Shares of Common Stock Underwriting Agreement Download Save ShareCiteReport Exhibit 1.1 EXECUTION VERSION ALNYLAM PHARMACEUTICALS, INC. 4,736,842 Shares of Common Stock Underwriting Agreement January 20, 2015 X.X. Xxxxxx Securities LLC 000 Xxxxxxx Xxxxxx Xxx Xxxx, Xxx Xxxx ...
Alnylam Pharmaceuticals (ALNY) 277.16 +0.85 (+0.31%) 15:46 ET [NASDAQ] Financial Summary for Thu, Feb 6th, 2025 Notes Alerts Watch Help Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The ...
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloid... 285.81USD Price –USD Fair Value – Upside ...